Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 5, and 7F. Our data do not support or exclude cross-protection against serotype 19A.
Mirjam J
MJ
Knol
Gertjan H J
GH
Wagenvoort
Elisabeth A M
EA
Sanders
Karin
K
Elberse
Bart J
BJ
Vlaminckx
Hester E
HE
de Melker
Arie
A
van der Ende
D006801:Humans; D032521:Immunity, Herd / Q000187:drug effects; D015994:Incidence; D009426:Netherlands / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D022242:Pneumococcal Vaccines / Q000276:immunology / Q000627:therapeutic use*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000276:immunology / Q000472:pathogenicity; D018074:Vaccines, Conjugate / Q000276:immunology / Q000627:therapeutic use
C586648:10-valent pneumococcal conjugate vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
10-valent pneumococcal conjugate vaccine; 7-valent pneumococcal conjugate vaccine; IPD; PCV10; PCV7; Streptococcus pneumoniae; incidence; invasive pneumococcal disease; streptococci; surveillance; the Netherlands; vaccine switching